Insilico’s $2.5b AI drug discovery deal targets neuroimmune failure (opens in new tab)

Partnership with SK Biopharma signals growing confidence that AI can accelerate search for treatments for some of brain’s toughest diseases. For all the excitement surrounding AI, one question still hangs over the biotechnology sector: can AI actually help deliver better medicines? A new collaboration between generative AI-driven drug discovery company Insilico Medicine and Korean-based biotech […] The post appeared first on <a href="